Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abvc Biopharma Inc (NQ: ABVC )

2.080 -0.010 (-0.48%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,402
Open 2.100
Bid (Size) 2.080 (3)
Ask (Size) 2.250 (20)
Prev. Close 2.090
Today's Range 2.080 - 2.210
52wk Range 1.950 - 9.480
Shares Outstanding 24,470,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures COVID-19
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety

Performance

YTD
-37.91%
-37.91%
1 Month
-18.75%
-18.75%
3 Month
-17.13%
-17.13%
6 Month
-38.28%
-38.28%
1 Year
-30.43%
-30.43%

More News

Read More
90 Biggest Movers From Yesterday
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
Via NewMediaWire
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
Via NewMediaWire
ABVC BioPharma Announces Streamlined Vitargus(R) Manufacturing Process
Via NewMediaWire
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
Via NewMediaWire
Exposures Product Safety
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
Via NewMediaWire
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
Via NewMediaWire
ABVC Biopharma Announces Fiscal Year 2021 Financial and Operational Results
Via NewMediaWire
ABVC BioPharma to Present at the Maxim Group 2022 Virtual Growth Conference
Via NewMediaWire
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
Via NewMediaWire
87 Biggest Movers From Yesterday
Via Benzinga
From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances
Via Benzinga
ABVC BioPharma Selects Additional Vitargus Phase II Study Sites
Via NewMediaWire
ABVC BioPharma's Vitreous Substitute Vitargus Presented at 14th APVRS Congress
Via NewMediaWire
Mobile Clinics Featuring Novel Mental Health Treatments Reportedly Coming to Florida and Nevada
Via Benzinga
ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award
Via NewMediaWire
This Biotech Company Specializing in Brain Disorder Treatments Reports a Stronger Cash Position
Via Benzinga
Why ABVC BioPharma Shares Are Trading Higher On Friday?
Via Benzinga
ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement
Via NewMediaWire
Exposures COVID-19
ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results
Via NewMediaWire
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
28 Stocks Moving in Thursday's Pre-Market Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.